share_log

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics收到了美国食品药品管理局关于推进Imc-2(伐昔洛韦+塞来昔布的组合)作为疲劳、体位不耐受和其他与长期Covid疾病相关的症状的治疗的要求的反馈
Benzinga ·  01/02 07:09

Virios Therapeutics Received FDA Feedback On Requirements For Advancing Imc-2 (Combination Of Valacyclovir + Celecoxib) As A Treatment For Fatigue, Orthostatic Intolerance, And Other Symptoms Associated With Long Covid Illness

Virios Therapeutics收到了美国食品药品管理局关于推进Imc-2(伐昔洛韦+塞来昔布的组合)作为疲劳、体位不耐受和其他与长期Covid疾病相关的症状的治疗的要求的反馈

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发